Twist Bioscience Corp
For the period ended Dec 31, 2023. Filed Feb 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 2, 2024
TWST$132.13-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
| Three months endedDecember 31, | ||
|---|---|---|
| (In thousands, except per share data) | 2023 | 2022 |
| Revenues [1] | $71,498 | $54,243 |
| Operating expenses: | ||
| Cost of revenues | $42,536 | $29,442 |
| Research and development | 23,099 | 31,242 |
| Selling, general and administrative | 52,840 | 42,324 |
| Change in fair value of contingent considerations and holdbacks | — | $(4,135) |
| Total operating expenses | $118,475 | $98,873 |
| Loss from operations | $(46,977) | $(44,630) |
| Interest income | 4,120 | 3,040 |
| Interest expense | — | (1) |
| Other income (expense), net | (31) | (157) |
| Loss before income taxes | $(42,888) | $(41,748) |
| Income tax provision | (120) | $(76) |
| Net loss attributable to common stockholders | $(43,008) | $(41,824) |
| Other comprehensive loss: | ||
| Change in unrealized (gain) loss on investments | $134 | (868) |
| Foreign currency translation adjustment | 57 | (366) |
| Comprehensive loss | (42,817) | (43,058) |
| Net loss per share attributable to common stockholders—basic and diluted | $(0.75) | $(0.74) |
| Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted | 57,497 | 56,444 |
[1]During the three months ended December 31, 2023, and 2022, the Company had revenues from the related parties in the amount of $2.3 million and $0.2 million, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.